$24.33
-0.70[-2.80%]
At close: Apr 25
$24.33
0[0.00%]
After Hours: 4:20PM EDT
BridgeBio Pharma
(NASDAQ:BBIO)BridgeBio Pharma Stock (NASDAQ:BBIO), Analyst Ratings, Price Targets, Predictions
BridgeBio Pharma Inc has a consensus price target of $46.75, established from looking at the 43 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Cantor Fitzgerald, and Cantor Fitzgerald on March 20, 2024, March 19, 2024, and March 11, 2024. With an average price target of $58.33 between JP Morgan, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 139.76% upside for BridgeBio Pharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Cantor Fitzgerald
Mizuho
HC Wainwright & Co.
Citigroup
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for BridgeBio Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/20/2024 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 84.96% | JP Morgan | Anupam Rama | $35 → $45 | Maintains | Overweight | Get Alert |
| 03/19/2024 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 187.71% | Cantor Fitzgerald | Josh Schimmer | $60 → $70 | Maintains | Overweight | Get Alert |
| 03/11/2024 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 146.61% | Cantor Fitzgerald | Josh Schimmer | $50 → $60 | Maintains | Overweight | Get Alert |
| 03/05/2024 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 117.84% | Mizuho | Salim Syed | $60 → $53 | Maintains | Buy | Get Alert |
| 03/04/2024 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 93.18% | HC Wainwright & Co. | Raghuram Selvaraju | → $47 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 89.07% | Citigroup | David Lebowitz | $42 → $46 | Maintains | Buy | Get Alert |
| 01/31/2024 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 52.08% | BMO Capital | Kostas Biliouris | → $37 | Initiates | → Market Perform | Get Alert |
| 01/29/2024 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 93.18% | HC Wainwright & Co. | Raghuram Selvaraju | $22 → $47 | Maintains | Buy | Get Alert |
| 01/22/2024 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 105.51% | Cantor Fitzgerald | Josh Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/07/2023 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 72.63% | Citigroup | David Lebowitz | → $42 | Initiates | → Buy | Get Alert |
| 10/24/2023 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 105.51% | Cantor Fitzgerald | Josh Schimmer | → $50 | Initiates | → Overweight | Get Alert |
| 08/28/2023 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 146.61% | Mizuho | Salim Syed | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/17/2023 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 56.19% | JP Morgan | Anupam Rama | $42 → $38 | Maintains | Overweight | Get Alert |
| 08/14/2023 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 146.61% | Mizuho | Salim Syed | $50 → $60 | Maintains | Buy | Get Alert |
| 07/18/2023 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 105.51% | Goldman Sachs | Paul Choi | $29 → $50 | Maintains | Buy | Get Alert |
| 07/18/2023 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 89.07% | Raymond James | Dane Leone | $29 → $46 | Maintains | Outperform | Get Alert |
| 07/18/2023 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 35.64% | Jefferies | Eun Yang | $24 → $33 | Downgrade | Buy → Hold | Get Alert |
| 05/08/2023 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 19.19% | Mizuho | Salim Syed | $23 → $29 | Maintains | Buy | Get Alert |
| 04/19/2023 | BBIO | Buy Now | BridgeBio Pharma | $24.33 | 64.41% | Evercore ISI Group | Josh Schimmer | → $40 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for BridgeBio Pharma (BBIO)?
The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by JP Morgan on March 20, 2024. The analyst firm set a price target for $45.00 expecting BBIO to rise to within 12 months (a possible 84.96% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BridgeBio Pharma (BBIO)?
The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by JP Morgan, and BridgeBio Pharma maintained their overweight rating.
When was the last upgrade for BridgeBio Pharma (BBIO)?
The last upgrade for BridgeBio Pharma Inc happened on September 10, 2021 when B of A Securities raised their price target to $75. B of A Securities previously had a neutral for BridgeBio Pharma Inc.
When was the last downgrade for BridgeBio Pharma (BBIO)?
The last downgrade for BridgeBio Pharma Inc happened on July 18, 2023 when Jefferies changed their price target from $24 to $33 for BridgeBio Pharma Inc.
When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on March 20, 2024 so you should expect the next rating to be made available sometime around March 20, 2025.
Is the Analyst Rating BridgeBio Pharma (BBIO) correct?
While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a maintained with a price target of $35.00 to $45.00. The current price BridgeBio Pharma (BBIO) is trading at is $24.33, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.